氯沙坦减轻化学烧伤诱导的角膜缘干细胞缺乏
该研究利用氮芥诱导的小鼠角膜损伤模型建立角膜缘干细胞缺乏(LSCD),腹腔注射氯沙坦进行干预。结果显示氯沙坦显著减轻急性和延迟期角膜混浊与炎症,减少延迟期角膜新生血管及杯状细胞浸润,并通过减少角膜单核/巨噬细胞发挥抗炎作用,支持氯沙坦作为LSCD潜在治疗药物的新用途。
要点
- 氯沙坦系统治疗减轻氮芥诱导小鼠角膜损伤急性和延迟期的角膜混浊与炎症。
- 氯沙坦减少延迟期角膜新生血管及角膜上皮内杯状细胞(结膜化标志)。
- 氯沙坦通过减少角膜单核/巨噬细胞浸润减轻炎症,scRNA-seq与流式细胞术均证实。
核心结论
- 氯沙坦系统治疗可减轻氮芥诱导的小鼠角膜缘干细胞缺乏(LSCD)相关角膜炎症、混浊、新生血管和结膜化。
研究设计与样本
- 研究采用氮芥诱导的小鼠角膜损伤模型建立LSCD,小鼠腹腔注射氯沙坦进行干预。
- 使用10X Genomics平台进行单细胞RNA测序(scRNA-seq),并以流式细胞术验证角膜单核/巨噬细胞变化。
主要发现
- 氯沙坦显著减少氮芥角膜损伤急性期和延迟期的角膜混浊与炎症。
- 延迟期氯沙坦治疗减少氮芥诱导的角膜新生血管。
- 延迟期角膜上皮内杯状细胞(结膜化)在氯沙坦治疗后显著减少,表明LSCD经典标志得到缓解。
- scRNA-seq显示氮芥损伤导致角膜单核/巨噬细胞大幅增加,氯沙坦治疗减弱该增加;流式细胞术证实氯沙坦通过减少角膜单核/巨噬细胞减轻炎症。
临床怎么用
- 氯沙坦作为长期安全性明确的抗高血压药物,可能被重新用于减轻LSCD相关角膜炎症和结膜化。
- 该发现支持氯沙坦在多种角膜炎症性疾病(如糖尿病性角膜病变和泪腺功能不全)所致LSCD中的潜在治疗价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Currently, treatment for limbal stem cell deficiency (LSCD) involves limbal stem cell transplantation using either autologous or allogeneic tissue to restore the corneal surface. However, limitations such as donor shortages, immune rejection, and variable outcomes highlight a crucial need for more effective and safer therapeutic options. METHODS: We utilized a nitrogen mustard (NM)-induced corneal injury model to create LSCD, characterized by conjunctivalization. Mice exposed to NM were intraperitoneally injected with losartan. Single cell RNA sequencing (scRNA-seq) was conducted using a 10X Genomics platform. RESULTS: Previously, we demonstrated that corneal inflammation can be reversed by treatment with losartan, a widely used anti-hypertension drug with established long-term safety. Here, we demonstrate that systemic treatment with losartan markedly decreased corneal haze and inflammation during the acute and delayed phases of NM corneal injury. In the delayed phase, losartan treatment reduced NM-induced neovascularization in the cornea. Goblet cells detected within the corneal epithelium (conjunctivalization) during the delayed phase were significantly reduced following losartan treatment, indicating that losartan significantly resolves this classical hallmark of LSCD. The scRNA-seq showed that NM injury induced a dramatic increase in monocytes/macrophages in the cornea and that such an increase was attenuated by losartan treatment. Flow cytometry analysis confirmed that losartan attenuated corneal inflammation via reducing the monocytes/macrophages in the cornea. CONCLUSIONS: Our findings strongly support a new therapeutic use for losartan in blunting LSCD, which is a consequence associated with numerous corneal inflammatory conditions (e.g. diabetic keratopathy and tear gland insufficiency).
引用
- Foroozandeh P, Kaplan N, Xu D, et al. Losartan Alleviates Chemical Burn-Induced Limbal Stem Cell Deficiency: Repurposing a Venerable Anti-Hypertension Drug. Invest Ophthalmol Vis Sci. 2026. PMID: 41537756. doi:10.1167/iovs.67.1.35
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。